The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma

The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma

Objective: In this post-hoc analysis, we evaluated anlotinib treatment-induced hypertension as a potential predictive factor of efficacy in esophageal squamous cell carcinoma (ESCC) patients. Methods: A total of 109 patients enrolled in the anlotinib group in a phase 2 trial were included. The tumor...

Full description

Bibliographic Details
Main Authors:	Yan Song, Juxiang Xiao, Wentao Fang, Ping Lu, Qingxia Fan, Yongqian Shu, Jifeng Feng, Shu Zhang, Yi Ba, Yang Zhao, Ying Liu, Chunmei Bai, Yuxian Bai, Yong Tang, Jie He, Jing Huang
Format:	Article
Language:	English
Published:	China Anti-Cancer Association 2021-05-01
Series:	Cancer Biology & Medicine
Subjects:	esophageal squamous cell carcinoma (escc) anlotinib treatment-induced hypertension prognostic predictor antiangiogenesis
Online Access:	http://www.cancerbiomed.org/index.php/cocr/article/view/1828

Similar Items

Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial
by: Jing Huang, et al.
Published: (2021-03-01)

Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients
by: Yu Qian, et al.
Published: (2022-12-01)

Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis
by: Hongchao Zhen, et al.
Published: (2023-03-01)

Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study
by: Ying Liu, et al.
Published: (2022-08-01)

Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review
by: Ran Zuo, et al.
Published: (2020-11-01)

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial
by: Ying Cheng, et al.
Published: (2020-04-01)

Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
by: Jingzhen Shi, et al.
Published: (2020-07-01)

Clinical Efficacy of Anlotinib Combined with Paclitaxel and Cisplatin as First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
by: YANG Xiaoli, et al.
Published: (2021-07-01)

Corrigendum: Anlotinib Combined With Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma
by: Jingzhen Shi, et al.
Published: (2020-11-01)

Feasibility and Safety of Anlotinib Monotherapy for Patients with Previously Treated Advanced Esophageal Squamous Cell Carcinoma: A Real-World Exploratory Study
by: Zhang S, et al.
Published: (2022-05-01)

Plasma-metabolite-based machine learning is a promising diagnostic approach for esophageal squamous cell carcinoma investigation
by: Zhongjian Chen, et al.
Published: (2021-08-01)

Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma
by: Bailing Jiang, et al.
Published: (2020-02-01)

A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma
by: Ning Li, et al.
Published: (2022-12-01)

Characterization of Esophageal Microbiota in Patients With Esophagitis and Esophageal Squamous Cell Carcinoma
by: Zongdan Jiang, et al.
Published: (2021-11-01)

Case Report: Toripalimab Combined With Anlotinib in a Patient With Metastatic Upper Tract Urothelial Carcinoma After Pembrolizumab Failure
by: Ning Zan, et al.
Published: (2022-02-01)

Microarray Analysis of Radioresistance-associated Genes in Esophageal Squamous Cell Carcinoma
by: ZHU Qingshan, et al.
Published: (2019-03-01)

The Predictive Value of Systemic Inflammatory Factors in Advanced, Metastatic Esophageal Squamous Cell Carcinoma Patients Treated with Camrelizumab
by: Liu J, et al.
Published: (2022-10-01)

A Nomogram Model to Predict Post-Progression Survival in Esophageal Squamous Cell Carcinoma Patients With Recurrence After Radical Resection
by: Changsen Leng, et al.
Published: (2022-07-01)

Prevalence and Association of Human Papillomavirus with Esophageal Squamous Cell Carcinoma in Iran: A Systematic Review and Meta-Analysis
by: Bashir MOHAMMADPOUR, et al.
Published: (2019-07-01)

Neoadjuvant Anlotinib and chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced esophageal squamous cell carcinoma: Short-term results of an open-label, randomized, phase II trial
by: Ying-Jian Wang, et al.
Published: (2022-08-01)

Occupational risks of esophageal cancer in Taiwanese men
by: Shih-Hui Huang, et al.
Published: (2012-12-01)

Current advances and future perspectives on the functional roles and clinical implications of circular RNAs in esophageal squamous cell carcinoma: more influential than expected
by: Chenxi Ju, et al.
Published: (2022-06-01)

Clinical value of station 4R node dissection in esophageal squamous cell carcinoma
by: Xin-ye Wang, et al.
Published: (2023-12-01)

Drug repositioning for esophageal squamous cell carcinoma
by: Adam N. Bennett, et al.
Published: (2022-09-01)

Expression of fibronectin in esophageal squamous cell carcinoma and its role in migration
by: Jiefei Xiao, et al.
Published: (2018-10-01)

Global research trend of esophageal squamous cell carcinoma from 2012 to 2022: a bibliometric analysis
by: Zehua Zhang, et al.
Published: (2022-08-01)

Predictive Value of LINC01133 for Unfavorable Prognosis was Impacted by Alcohol in Esophageal Squamous Cell Carcinoma
by: Xian-Zi Yang, et al.
Published: (2018-07-01)

Development and Validation of a Ferroptosis-Related Gene Signature and Nomogram for Predicting the Prognosis of Esophageal Squamous Cell Carcinoma
by: Jiecheng Ye, et al.
Published: (2021-10-01)

Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study
by: Zhang K, et al.
Published: (2020-05-01)

SPI1-Mediated Upregulation of the CST1 Gene as an Independent Poor Prognostic Factor Accelerates Metastasis in Esophageal Squamous Cell Carcinoma (ESCC) by Interacting with MMP2
by: Fei-Fei Luo, et al.
Published: (2023-09-01)

Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer
by: Zhe Zhang, et al.
Published: (2023-04-01)

Capn4 promotes esophageal squamous cell carcinoma metastasis by regulating ZEB1 through the Wnt/β‐catenin signaling pathway
by: Yun‐Long Zhao, et al.
Published: (2019-01-01)

AURKA knockdown inhibits esophageal squamous cell carcinoma progression through ferroptosis
by: Yuan Mi, et al.
Published: (2024-04-01)

Identifying LATS2 as a prognostic biomarker relevant to immune infiltrates in human esophageal squamous cell carcinoma
by: Minqi Zhu, et al.
Published: (2022-09-01)

circGSK3β promotes metastasis in esophageal squamous cell carcinoma by augmenting β-catenin signaling
by: Xueting Hu, et al.
Published: (2019-11-01)

Analysis of SEPT9 Gene Promoter Methylation Status in Esophageal Squamous Cell Carcinoma
by: Aida Mirza Aghasi, et al.
Published: (2020-01-01)

Optimal Range of Lymphadenectomy in Pathological Stage T1 and T2 Esophageal Squamous Cell Carcinoma
by: Hansheng Wu, et al.
Published: (2021-05-01)

Metformin in Esophageal Carcinoma: Exploring Molecular Mechanisms and Therapeutic Insights
by: Stavros P. Papadakos, et al.
Published: (2024-03-01)

High TLR6 Expression Status Predicts a More Favorable Prognosis after Esophagectomy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
by: Yusuke Sato, et al.
Published: (2023-05-01)

Perioperative tislelizumab plus chemotherapy for locally advanced resectable thoracic esophageal squamous cell carcinoma trial: a prospective single-arm, phase II study (PILOT trial)
by: Chengzhi Ding, et al.
Published: (2023-12-01)